Overview

UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma

Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and in vivo persistence and expansion of autologous and expansion of autologous, ex vivo expanded-natural killer(ENK) cells.
Phase:
Phase 2
Details
Lead Sponsor:
University of Arkansas
Collaborator:
Millennium Pharmaceuticals, Inc.